Comparative Pharmacology
Head-to-head clinical analysis: FERUMOXYTOL versus TRILITRON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FERUMOXYTOL versus TRILITRON.
FERUMOXYTOL vs TRILITRON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ferumoxytol is an ultrasmall superparamagnetic iron oxide nanoparticle that provides a source of iron for erythropoiesis. It is phagocytosed by macrophages of the reticuloendothelial system, and iron is released intracellularly to bind to transferrin and ferritin, replenishing iron stores.
TRILITRON is a non-steroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis and thereby alleviating pain and inflammation.
510 mg intravenously once, followed by 510 mg intravenously 3 to 8 days later for a total cumulative dose of 1020 mg. Administer as a slow IV injection at 1 mL/min (30 mg/min) undiluted or diluted in 50-200 mL normal saline.
10 mg orally once daily, with or without food.
None Documented
None Documented
Terminal elimination half-life is approximately 14-21 hours in healthy adults; prolonged in patients with iron deficiency anemia (up to 30 hours) due to increased iron utilization.
Terminal elimination half-life is 12-15 hours, allowing twice-daily dosing. Steady-state reached in 2-3 days.
Ferumoxytol is eliminated primarily through the reticuloendothelial system, with the iron moiety incorporated into hemoglobin or stored as ferritin/hemosiderin. Minimal renal or biliary excretion of intact drug; <1% excreted unchanged in urine.
Primarily renal excretion of unchanged drug (60-70%) and glucuronide conjugate (15-20%). Biliary/fecal elimination accounts for 10-15%.
Category C
Category C
Iron Replacement
Iron Replacement